No insulin is truly weight-neutral, but some formulations cause significantly less weight gain than others. Insulin detemir consistently shows the smallest weight increase among injectable basal insulins, and inhaled insulin appears to cause less gain than injected rapid-acting options. The biggest shift in recent years, though, comes from combining basal insulin with a GLP-1 receptor agonist, which can result in actual weight loss rather than gain.
Why All Insulin Promotes Some Weight Gain
Insulin is the body’s primary storage hormone. It pushes glucose into cells for energy, promotes fat and glycogen storage, and suppresses the release of fatty acids from fat tissue. When you start insulin therapy or increase your dose, your body becomes more efficient at storing fuel rather than burning it. Calories that were previously lost through high blood sugar (literally excreted in urine) now get used and stored. This is a sign the treatment is working, but it comes with a predictable side effect: weight gain, typically ranging from 1 to 5 kilograms in the first year depending on the type and dose.
Higher doses amplify the effect. Clinical data show that daily insulin doses above 0.5 units per kilogram of body weight produce greater weight gain than lower doses, without proportionally better blood sugar control. That diminishing return is one reason clinicians try to keep doses as low as effective.
How Basal Insulins Compare
The three most commonly used long-acting basal insulins are glargine (Lantus, Basaglar, Toujeo), detemir (Levemir), and degludec (Tresiba). All cause weight gain, but the amount differs.
In a pooled analysis comparing glargine and detemir head to head, patients on glargine gained an average of 2.5 kg while those on detemir gained 1.7 kg. That difference of roughly 0.8 kg was borderline statistically significant. However, when researchers adjusted for how much each insulin lowered blood sugar, the gap disappeared. In other words, detemir produced slightly less weight gain partly because patients sometimes needed higher doses to achieve the same blood sugar reduction, and the per-unit weight effect was similar.
Degludec falls in a similar range. In a 52-week study of people with type 1 diabetes, degludec users gained an average of 1.2 kg. In type 2 diabetes patients on a more intensive basal-bolus regimen, the gain was larger at about 3.6 kg over the same period. The more insulin you take total, the more weight you can expect to gain, regardless of which brand you use.
If minimizing weight gain is a priority and you’re choosing between basal insulins alone, detemir has the most consistent track record for the smallest increase. But the differences between these options are modest.
Inhaled Insulin: A Lower-Gain Option
Inhaled insulin (Afrezza) delivers rapid-acting insulin through the lungs instead of a subcutaneous injection. Clinical data show it produces less weight gain and fewer episodes of low blood sugar compared to injected rapid-acting insulins, while providing similar blood sugar control. The faster absorption and shorter duration of action may explain why less insulin circulates at levels that promote fat storage.
Inhaled insulin only covers mealtime needs, so it doesn’t replace a basal insulin. It’s an option worth discussing if you’re on a basal-bolus regimen and the mealtime component is contributing to unwanted weight. It’s not appropriate for everyone, particularly people with chronic lung conditions like asthma or COPD.
Insulin Plus GLP-1: The Combination That Changes the Equation
The most effective strategy for avoiding insulin-related weight gain isn’t choosing a different insulin. It’s pairing basal insulin with a GLP-1 receptor agonist. These medications (like liraglutide, semaglutide, or lixisenatide) slow digestion, reduce appetite, and improve blood sugar control through pathways that don’t involve fat storage.
A fixed-ratio combination of insulin glargine and lixisenatide (sold as Soliqua) illustrates this clearly. Over 30 weeks, patients on the combination lost an average of 0.67 kg, while those on insulin glargine alone gained 0.70 kg. That’s a net difference of about 1.4 kg favoring the combination, with better blood sugar numbers and no increase in dangerous low blood sugar episodes.
Standalone GLP-1 drugs like semaglutide produce even more weight loss on their own, which is why many people with type 2 diabetes now start a GLP-1 agonist before or alongside insulin rather than using insulin alone. For people already on insulin who are gaining weight, adding a GLP-1 can partially or fully offset the gain.
How Metformin Helps Offset the Gain
Metformin is the most widely used oral diabetes medication and has a mild weight-reducing effect. When used alongside insulin, it can blunt weight gain by about 2 to 3 kg compared to insulin without metformin. It works by reducing glucose production in the liver, which means you may need less insulin overall. Lower insulin doses mean less of the storage signal driving fat accumulation.
Most people with type 2 diabetes are already on metformin before starting insulin, so this benefit is often built in. If you’re on insulin and not taking metformin, it’s worth asking whether adding it could help manage both blood sugar and weight.
Type 1 vs. Type 2: Different Patterns
Weight gain from insulin looks different depending on your type of diabetes. People with type 1 diabetes often start insulin at diagnosis when they’re underweight from uncontrolled blood sugar, so some initial weight gain is actually recovery. The ongoing gain tends to be smaller because type 1 patients produce no insulin naturally and their doses are usually lower relative to body weight.
In type 2 diabetes, insulin resistance means the body needs much higher doses to achieve the same effect. Those higher doses drive more fat storage. People with type 2 diabetes also tend to start with a higher baseline weight, making additional gain more concerning for cardiovascular and metabolic health. This is the group where combination strategies (adding GLP-1 agonists or metformin, keeping doses as low as possible) have the biggest impact.
Practical Ways to Minimize Insulin-Related Weight Gain
- Keep carbohydrate intake consistent. Fewer blood sugar spikes mean fewer correction doses and less total insulin exposure.
- Stay physically active. Exercise increases insulin sensitivity, which lets you achieve the same blood sugar control with a lower dose.
- Ask about combination therapy. Pairing insulin with a GLP-1 agonist or ensuring metformin stays in your regimen can counteract weight gain without sacrificing blood sugar control.
- Monitor dose creep. Doses above 0.5 units per kilogram per day produce diminishing blood sugar benefits with increasing weight gain. If your dose keeps climbing, it may be time to revisit your overall treatment plan.
- Consider detemir or inhaled insulin. If you have flexibility in your insulin choice, these options carry slightly less weight impact than alternatives.